CASREVOLUTION s.r.l.
CASREVOLUTION SRL: THE CASR RECEPTOR FOR ALZHEIMER’S TREATMENT
The company has identified a development plan through in-depth literature analyses focused on Alzheimer’s disease, the CaSR transmembrane receptor, and the possible molecules known to modulate the CaSR receptor response.
Through the conducted research, the company believes, with the support of selected research institutes, it can develop new molecules capable of crossing the blood-brain barrier and thus actively acting on the CaSR transmembrane receptor.
This receptor is apparently responsible for the degeneration of astrocytes and neurons, and therefore Alzheimer’s disease. These new molecules will be developed from known molecules capable of modulating calcium levels in the body.
Additionally, the Board of Directors includes Andrea Pellacani, a physician and manager with thirty years of experience in the United States, currently heading the R&D department at Alfasigma SpA.
Utopia, along with industry professionals like Elena Zambon, Chiara Zambon, and Luca Benatti, invested in May 2023.
